02.05.19
India-based Enzene Biosciences has chosen Novasep’s BioSC Pilot for purification of biopharmaceuticals to operate in its Pune plant.
BioSC Pilot is dedicated to the purification of biomolecules such as monoclonal antibodies (mAbs), from early pilot phase to small commercial production. Enzene says the platform fits its ambition to deliver cost effective biosimilars by developing disruptive technology, advanced analytics and a state-of-the-art manufacturing facility.
Enzene is an innovation driven and one of the fastest growing biotech companies from Pune, India. Enzene has developed multiple novel and advanced technological platforms with an aim to disrupt the affordability of biotech products globally. Enzene, a subsidiary of Alkem laboratories—one of the top ten pharmaceutical companies in India—is amongst first movers in end-to-end connected biomanufacturing and is setting up a fully automated continuous cGMP compliant manufacturing plant for mAb production.
"Most of the biotech medicines remain inaccessible due to their high cost. Our goal is to edit the script of bio-manufacturing by drastically reducing the manufacturing cost to make these lifesaving medicines affordable across the globe,” said Himanshu Gadgil, director and chief science officer, Enzene. “With this goal we have significantly invested in the facility which will be operational shortly. We are happy to acquire BioSC from Novasep which we believe will further enhance our novel manufacturing platform.”
BioSC Pilot modular design makes it easy to combine different chromatography modules such as batch and multi-column continuous chromatography. Other intermediate steps such as buffer preparation, tangential flow filtration, and viral inactivation can also be integrated. The chaining of multiple processes leads to the removal of non-added value intermediate steps and results in a streamlined and intensified process.
"The growing demand for biopharmaceuticals and the constant pressure on productivity leads the biotech industry to rethink their manufacturing practices," said Nadège Laborde, president, process solutions business unit, Novasep. "BioSC Pilot is the perfect asset to help our customers implement continuous and intensified manufacturing for their downstream processes and reduce the time-to-market of their products."
BioSC Pilot is dedicated to the purification of biomolecules such as monoclonal antibodies (mAbs), from early pilot phase to small commercial production. Enzene says the platform fits its ambition to deliver cost effective biosimilars by developing disruptive technology, advanced analytics and a state-of-the-art manufacturing facility.
Enzene is an innovation driven and one of the fastest growing biotech companies from Pune, India. Enzene has developed multiple novel and advanced technological platforms with an aim to disrupt the affordability of biotech products globally. Enzene, a subsidiary of Alkem laboratories—one of the top ten pharmaceutical companies in India—is amongst first movers in end-to-end connected biomanufacturing and is setting up a fully automated continuous cGMP compliant manufacturing plant for mAb production.
"Most of the biotech medicines remain inaccessible due to their high cost. Our goal is to edit the script of bio-manufacturing by drastically reducing the manufacturing cost to make these lifesaving medicines affordable across the globe,” said Himanshu Gadgil, director and chief science officer, Enzene. “With this goal we have significantly invested in the facility which will be operational shortly. We are happy to acquire BioSC from Novasep which we believe will further enhance our novel manufacturing platform.”
BioSC Pilot modular design makes it easy to combine different chromatography modules such as batch and multi-column continuous chromatography. Other intermediate steps such as buffer preparation, tangential flow filtration, and viral inactivation can also be integrated. The chaining of multiple processes leads to the removal of non-added value intermediate steps and results in a streamlined and intensified process.
"The growing demand for biopharmaceuticals and the constant pressure on productivity leads the biotech industry to rethink their manufacturing practices," said Nadège Laborde, president, process solutions business unit, Novasep. "BioSC Pilot is the perfect asset to help our customers implement continuous and intensified manufacturing for their downstream processes and reduce the time-to-market of their products."
